<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04825340</url>
  </required_header>
  <id_info>
    <org_study_id>F202110111</org_study_id>
    <nct_id>NCT04825340</nct_id>
  </id_info>
  <brief_title>To Explore a Bridging Index for the Effectiveness of the Clinical Trial</brief_title>
  <official_title>To Explore a Bridging Index for the Effectiveness of the Clinical Trial With Nasal Spray Lyophilized Live Attenuated Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changchun BCHT Biotechnology Co.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changchun BCHT Biotechnology Co.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore a bridging index for the effectiveness of the clinical trial with Nasal Spray&#xD;
      Lyophilized Live Attenuated Influenza Vaccine&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With a randomized, blind, parallel placebo-controlled design, to screen the susceptible&#xD;
      individuals aged 3~59 years old whose titers of either of Hi antibody level of H1N1, H3N2 or&#xD;
      B are not higher than 1:10 prior immunization , in which all persons are to be assigned into&#xD;
      the two subgroups (aged 3~17 and 18~59 years old) with radio of 1:1, individually. All&#xD;
      persons of each age subgroups are to be randomly assigned into the two groups (vaccine or&#xD;
      placebo group) with th radio of 2:1 via intranasal injection of one dose of the study vaccine&#xD;
      or placebo. The blood samples are to be collected prior immunisation and on the 21st day post&#xD;
      immunisation, individually, the nasopharyngeal swab samples are also to be done prior&#xD;
      immunisation and on the 10th day and 21st day post immunisation, individually, and the levels&#xD;
      of serum HI antibody and mucous sIgA antibody are to be compared between the two groups,&#xD;
      respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 16, 2021</start_date>
  <completion_date type="Anticipated">March 25, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 25, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The GMTs of serum HI antibodies of all H1N1, H3N2 and B</measure>
    <time_frame>0-21 days</time_frame>
    <description>The GMTs of serum HI antibodies of all H1N1, H3N2 and B on the 21st day post immunization;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GMTs of HI sIgA antibodies of all H1N1, H3N2 and B</measure>
    <time_frame>10-21 days</time_frame>
    <description>The mucous GMTs of HI sIgA antibodies of all H1N1, H3N2 and B on the 10th and 21st day post immunization;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ratios and 95% CI of the GMTs of serum HI antibodies of all H1N1, H3N2 and B</measure>
    <time_frame>0-21days</time_frame>
    <description>The ratios and 95% CI of the GMTs of serum HI antibodies of all H1N1, H3N2 and B on the 21st day post immunization;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Randomized</condition>
  <arm_group>
    <arm_group_label>Study vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nasal Spray Lyophilized Live Attenuated Influenza Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>commercial normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nasal Spray Lyophilized Live Attenuated Influenza Vaccine</intervention_name>
    <description>0.2 ml/vial, 0.2ml/dose/per person</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Study vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. healthy volunteer aged 3~59 years old；&#xD;
&#xD;
          2. no vaccination with any influenza vaccine within the past year；&#xD;
&#xD;
          3. no catching any influenza or flu like symptoms （axillary temperature ≥ 38℃，&#xD;
             accompanied by cough or sore throat ）；&#xD;
&#xD;
          4. influenza susceptible individual（any serum Hi antibody level of H1N1, H3N2 and&#xD;
             B≦1:10）；&#xD;
&#xD;
          5. with informed consent obtained from the volunteer and / or guardian；&#xD;
&#xD;
          6. willing of volunteers and / or guardians to comply with the requirements of the&#xD;
             clinical trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known allergy individual to any ingredient of this product, including egg protein,&#xD;
             subsidiary material and/or gentamycin sulfate;&#xD;
&#xD;
          2. patients with acute disease, severe chronic disease, acute attack of chronic disease&#xD;
             and/or fever (axillary temperature ≥ 37.3℃ on the day of immunisation);&#xD;
&#xD;
          3. pregnancy (enquire);&#xD;
&#xD;
          4. patients with Leigh syndrome treated with aspirin or aspirin containing drugs;&#xD;
&#xD;
          5. patients with immunodeficiency or receiving immunosuppressive therapy;&#xD;
&#xD;
          6. patients with uncontrolled epilepsy and other progressive nervous system diseases,&#xD;
             with a history of Guillain Barre syndrome;&#xD;
&#xD;
          7. patients with rhinitis or other nasal abnormalities judged by clinicians that may&#xD;
             affect vaccination or sample collection;&#xD;
&#xD;
          8. accept any immunoglobulin and / or any blood products within 3 months, or plan to use&#xD;
             them during the study (until post immunization blood sample collection);&#xD;
&#xD;
          9. .taking anti influenza drugs in the past 48 hours;&#xD;
&#xD;
         10. .any situation that the researchers believe may affect the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccine Nasal Spray</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

